In a multivariable model adjusting for average CRP level, baseline SHS, and baseline adiponectin level, each log unit higher level of anti-PAD2 was associated with a 9% lower odds of radiographic joint disease progression (adjOR = 0.91; p = 0.016) (Figure 3C). Here, ADIPOQ is linked to arthropathy.